BDX Stock Forecast & Price Target

Becton Dickinson's diverse revenue streams from its various segments contribute to a robust financial outlook, with BD Medical Essentials, Interventional, Connected Care, and Biopharma representing 34%, 28%, 25%, and 13% of revenue, respectively. The company is anticipated to experience sustained volume growth in China, aided by the progress of volume-based procurement covering approximately 80% of its portfolio by the end of 2026, along with entering a growing $400 million Biosurgery market. Additionally, BD's Connected Care segment reported a notable year-over-year sales increase of 4.7%, highlighting the company's ability to achieve competitive wins and expand market share, particularly through the successful relaunch of Alaris.

Becton Dickinson is facing several challenges that contribute to a negative outlook for its stock, particularly due to a projected decline in revenue growth despite efforts to innovate and enhance commercial capabilities. The company is experiencing ongoing margin pressures from business investments, tariffs, and potential M&A dilution, alongside substantial headwinds in key markets like China, which are exacerbated by new regulations. Additionally, the anticipated overhang from the remediation cycle is expected to significantly drag on total company growth, with estimates suggesting a 100 basis point impact in fiscal year 2026 and a worsening 200 basis point impact in fiscal year 2027.